Navigation Links
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Date:5/7/2009

ly following infusion of study drug (i.e., during the first hour of treatment) in patients receiving ANX-514 relative to those receiving Taxotere, but, at 10 minutes after the completion of infusion, docetaxel blood-levels were comparable and remained so through the end of the observation period. The Company is analyzing these short-term increased levels, which were the reason ANX-514 was outside the bounds established by the FDA for determining bioequivalence. Analyzing blood-levels at all time points beginning 10 minutes after the completion of drug administration, pharmaceutical equivalence of ANX-514 and Taxotere was observed.

The bioequivalence study of ANX-514 was an open-label, two-period, randomized, crossover comparison of ANX-514 and Taxotere in patients with advanced cancer potentially sensitive to docetaxel. The primary objective was demonstrating the pharmacokinetic equivalence of ANX-514 and Taxotere and determining the safety of a single dose of ANX-514 was a secondary objective. On Day 1, patients were dosed with either ANX-514 or Taxotere and, on Day 22, were dosed with the other drug. Patients were premedicated with corticosteroids prior to treatment on Day 1 and on Day 22. The FDA has indicated that this single bioequivalence study, should it demonstrate pharmacokinetic equivalence between ANX-514 and Taxotere, would provide sufficient data to support an NDA.

Pharmacokinetic equivalence was assessed by a statistical comparison of both the areas under the curve (AUC) and maximum plasma concentrations (Cmax) and determined based on federal regulations and FDA guidance regarding bioequivalence studies. If the upper and lower bounds of the AUC ratio's and the Cmax ratio's 90% confidence interval ranged from 0.80 to 1.25, ANX-514 and Taxotere would be considered to have equivalent pharmacokinetics. Pursuant to the study's protocol and statistical analysis plan, data from 31 patients who received both
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
4. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
5. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
8. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 Research and Markets  has announced the ... Report, 2014-2017" report to their offering. ... recombinant protein drug market has been expanding rapidly owing ... the like. During 2005-2013, sales of recombinant protein drugs ... of 19.1%, and it is projected that ...
(Date:11/21/2014)... SAN DIEGO , Nov. 21, 2014 /PRNewswire/ ... TNDM ), a medical device company and ... today announced a partnership with Tidepool, a non-profit ... an open source software platform that increases diabetes ... the Tidepool Platform, which is currently under development, ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... a stock purchase agreement to acquire 100% of QCR ... based distribution organization. The transaction closed on ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... Inc.,(NYSE:MDT) today announced that a review of ... that the trial has met its primary,non-inferiority ... a randomized, single-blind,trial evaluating the safety and ... as compared to the TAXUS Paclitaxel-Eluting,Coronary Stent ...
... Cardiovascular Target from Lexicon's Genetic,Research -, ... /PRNewswire-FirstCall/ --,Lexicon Pharmaceuticals, Inc. today reported ... directed to a,potential new target, angiopoietin-like ... cholesterol. Research suggests that,a monoclonal antibody ...
Cached Medicine Technology:ENDEAVOR IV Clinical Trial Meets Primary Endpoint 2Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 2Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 3Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 4Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease 5
(Date:11/22/2014)... 22, 2014 Recently, UWDress.com is gratified ... guest dresses . In addition, the company has also ... , As a leading online supplier of wedding dresses, ... outfits. The unusual best wedding guest gowns are provided ... amazing designs, this new selection is famous for high ...
(Date:11/22/2014)... Sandbridge Capital, a private equity firm ... brand sector, acquired a minority stake in BackJoy ... help fund BackJoy’s global growth and accelerate the ... apparel and footwear lines. Sandbridge Capital Managing Partner ... , BackJoy is a high-growth health and wellness ...
(Date:11/22/2014)... 2014 “Greenfield Naturals” was featured on ... , which features the latest and coolest technology products ... reporter for NewsWatch, conducted the product review and shared ... of your water. , From pollution to hazardous substances ... everything is done to remove these chemicals, especially in ...
(Date:11/22/2014)... -- A clinical trial of hydroxyurea therapy for children ... early because the results show it is a safe ... the risk of stroke. The announcement about the ... the United States and Canada, was made this week ... (NHLBI). Researchers compared monthly blood transfusions with daily ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. ... patients are treated in an ambulance by a neurologist equipped ... The sooner patients get the clot dissolver -- tissue ... stroke, the researchers noted. For the best outcome, the drug ... symptoms start, the researchers said. "The so-called ,golden hour, ...
Breaking Medicine News(10 mins):Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... April 30 New data is showing a ... children in this country.,Here,s more on one group,s ... Listen to this report from Safe Kids Worldwide ... video, audio, text, graphics and,photos for free and ...
... eligible Medicaid members, PHOENIX, April 30 ... law, allowing the state Medicaid program to,expend moneys ... Introduced by Sen. Barbara Leff (R-Paradise Valley), ... state,s General Fund and will provide benefits,for nicotine ...
... in relapsing remitting illness , , WEDNESDAY, April 30 (HealthDay ... people with the relapsing remitting form of multiple sclerosis ... the disease were randomly selected to receive either 20 ... for 24 weeks. MRI brain scans were conducted every ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharmaceutical ... candidates principally,for use in the hospital setting, today ... results before the market opens on Tuesday, May ... call and live webcast to,discuss the financial results ...
... to Both Reduce Exacerbations ... and Improve Lung Function, ... and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone propionate 250 ... exacerbations in patients with chronic obstructive,pulmonary disease (COPD) who have ...
... Activity in Child Care Focuses on Child Care Providers, Perspectives; Cincinnati, ... ... Annual Meeting, CINCINNATI, April 30 At a time when ... growing concern over,childhood obesity has led physicians to focus on whether children ...
Cached Medicine News:Health News:Governor Napolitano Signs Smoking Cessation Bill 2Health News:Prozac Reduces Disease Activity in MS Patients 2Health News:Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 2Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 3Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 4
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Medicine Products: